$19.47
1.35% today
Nasdaq, Feb 05, 04:17 pm CET
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$19.21
-2.65 12.12% 1M
-6.86 26.31% 6M
-1.66 7.95% YTD
-8.36 30.32% 1Y
-15.46 44.59% 3Y
-4.39 18.60% 5Y
+12.41 182.50% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.10 0.52%
ISIN
US3723032062
Symbol
GMAB
Sector

Key metrics

Market capitalization $12.20b
Enterprise Value $9.76b
P/E (TTM) P/E ratio 18.37
EV/FCF (TTM) EV/FCF 10.36
EV/Sales (TTM) EV/Sales 3.40
P/S ratio (TTM) P/S ratio 4.25
P/B ratio (TTM) P/B ratio 2.55
Revenue growth (TTM) Revenue growth 18.04%
Revenue (TTM) Revenue $2.87b
EBIT (operating result TTM) EBIT $931.50m
Free Cash Flow (TTM) Free Cash Flow $942.23m
Cash position $2.59b
EPS (TTM) EPS $1.05
P/E forward 15.97
P/S forward 4.06
EV/Sales forward 3.25
Short interest 0.27%
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Genmab - ADR forecast:

17x Buy
61%
10x Hold
36%
1x Sell
4%

Analyst Opinions

28 Analysts have issued a Genmab - ADR forecast:

Buy
61%
Hold
36%
Sell
4%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
2,873 2,873
18% 18%
100%
- Direct Costs 113 113
-
4%
2,760 2,760
-
96%
- Selling and Administrative Expenses 516 516
10% 10%
18%
- Research and Development Expense 1,313 1,313
25% 25%
46%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 932 932
4% 4%
32%
Net Profit 675 675
9% 9%
23%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Neutral
GlobeNewsWire
13 days ago
Company Announcement COPENHAGEN, Denmark; January 23, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 4,903 restricted stock units and 5,289 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nominally DKK 1.
Neutral
GlobeNewsWire
14 days ago
Company Announcement Net sales of DARZALEX ® in 2024 totaled USD 11,670 million Genmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; January 22, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product ( daratumumab ...
Neutral
GlobeNewsWire
about one month ago
Media Release COPENHAGEN, Denmark; January 03, 2025 Genmab A/S (Nasdaq: GMAB ) announced today that its CEO, Jan van de Winkel, Ph.D., will present a company update at the 4 3 rd Annual J.P. Morgan Healthcare Conference in San Francisco at 3:00 PM PST / 6:00 PM EST on January 1 4 , 202 5 , 12 :00 AM CET on January 15, 2025 . The live and archived webcast of the presentation will be available on...
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,204
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today